Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability
暂无分享,去创建一个
I. Zubizarreta | I. Pulido-Valdeolivas | P. Villoslada | A. Gallo | E. Solana | E. Martínez-Heras | M. Andorrà | C. Montejo | N. Solà-Valls | M. Sepúlveda | Y. Blanco | A. Saiz | S. Llufriu | A. Bisecco | R. Capuano | L. Villar | J. I. Fernández-Velasco | S. Alba-Arbalat | E. Martinez-Lapiscina | E. Lopez-Soley | Rocco Capuano | Irati Zubizarreta | Magí Andorrà | Núria Solà-Valls
[1] M. Ramanathan,et al. Neurofilament levels are associated with blood–brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis , 2020, Multiple Sclerosis.
[2] J. Frederiksen,et al. Intrathecal IgM as a Prognostic Marker in Multiple Sclerosis , 2020, Molecular Diagnosis & Therapy.
[3] M. Amato,et al. Prognostic role of intrathecal IgM synthesis in multiple sclerosis: Results from a clinical series , 2020, Multiple sclerosis.
[4] L. Kappos,et al. Neurofilament light levels are associated with long-term outcomes in multiple sclerosis , 2019, Multiple sclerosis.
[5] S. Gil-Perotín,et al. Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis , 2019, Front. Neurol..
[6] F. Paul,et al. Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosis , 2019, Neurology.
[7] P. Calabresi,et al. Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. , 2019, Multiple sclerosis and related disorders.
[8] M. Mühlau,et al. CSF parameters associated with early MRI activity in patients with MS , 2019, Neurology: Neuroimmunology & Neuroinflammation.
[9] D. Hunt,et al. Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case–control studies , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.
[10] A. Oturai,et al. Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis , 2018, Multiple sclerosis.
[11] K. Blennow,et al. Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis , 2018, Journal of Neuroinflammation.
[12] H. Tumani,et al. Intrathecal immunoglobulin M production: A promising high‐risk marker in clinically isolated syndrome patients , 2018, Annals of neurology.
[13] G. Fenu,et al. Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor? , 2018, Journal of Neurology.
[14] David H. Miller,et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.
[15] S. Ozakbas,et al. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results , 2017, Clinical Neurology and Neurosurgery.
[16] Pablo Villoslada,et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies , 2016, Neurology.
[17] J. Álvarez-cermeño,et al. Intrathecal lipid-specific oligoclonal IgM synthesis associates with retinal axonal loss in multiple sclerosis , 2016, Journal of the Neurological Sciences.
[18] T. Derfuss,et al. Optimizing treatment success in multiple sclerosis , 2015, Journal of Neurology.
[19] A. Muriel,et al. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis , 2015, European journal of neurology.
[20] J. Ranjeva,et al. Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual , 2012, Multiple sclerosis.
[21] Axel Petzold,et al. The OSCAR-IB Consensus Criteria for Retinal OCT Quality Assessment , 2012, PloS one.
[22] F. Cendes,et al. Quantitative MRI and Cerebrospinal Fluid Inflammatory Mediators in Brazilian Patients with Relapsing-Remitting Multiple Sclerosis before and after Treatment with Immunomodulators: A Longitudinal Study , 2012, Neuroimmunomodulation.
[23] Jeffrey A. Cohen,et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.
[24] J. Gómez-Rial,et al. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis , 2008, Multiple sclerosis.
[25] E. Merelli,et al. A multifactorial prognostic index in multiple sclerosis , 2008, Journal of Neurology.
[26] F. Barkhof,et al. Cerebrospinal Fluid IgM Index Correlates with Cranial MRI Lesion Load in Patients with Multiple Sclerosis , 2007, European Neurology.
[27] M. Calabrese,et al. Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[28] J. Masjuán,et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. , 2005, The Journal of clinical investigation.
[29] J. Masjuán,et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS , 2002, Neurology.
[30] J. Masjuán,et al. A sensitive and reproducible method for the detection of oligoclonal IgM bands. , 2001, Journal of immunological methods.
[31] P. Lambin,et al. Frequency and relevance of IgM intrathecal synthesis in multiple sclerosis , 1995, European journal of neurology.
[32] P. Monteyne,et al. Occurrence of oligoclonal IgM bands in the cerebrospinal fluid of neurological patients: An immunoaffinity-mediated capillary blot study , 1994, Journal of the Neurological Sciences.
[33] E. Thompson,et al. INTRATHECAL IMMUNOGLOBULIN M SYNTHESIS IN MULTIPLE SCLEROSIS , 1991 .
[34] E. Thompson,et al. Intrathecal synthesis of IgM in neurological diseases: A comparison between detection of oligoclonal bands and quantitative estimation , 1990, Journal of the Neurological Sciences.
[35] X. Montalban,et al. Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice. , 2015, Clinica chimica acta; international journal of clinical chemistry.
[36] Angel Alberich-Bayarri,et al. Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes , 2011, Neuroradiology.
[37] Wei Wang,et al. Antibody structure, instability, and formulation. , 2007, Journal of pharmaceutical sciences.